Why Is bioAffinity Technologies Stock Surging Tuesday?

bioAffinity Technologies Inc (NASDAQ: BIAF) shares surged 41.37% to $2.70 following the release of a clinical case study demonstrating the effectiveness of its CyPath Lung diagnostic tool. The study showed that a 71-year-old patient with pulmonary nodules received a 'Unlikely Malignancy' result, avoiding invasive procedures. The company reported an 87% year-over-year revenue growth for CyPath Lung in 2025, with tests performed increasing by 99%. Analysts anticipate a loss per share of $2.70 on revenue of $1.41 million in the upcoming fourth-quarter earnings report.